Mark Feinberg named president and CEO of IAVI
Feinberg has more than 30 years of experience in translational, basic and clinical HIV research efforts. He has integrative and broad perspectives on the industry thanks to leadership roles he had in government, academia and industry.
“Mark brings a wealth of relevant experience and the passion to lead IAVI through the next chapter of our journey toward an AIDS vaccine,” Alex Coutinho, IAVI board chair, said. “He shares IAVI’s strong commitment to program excellence, collaboration and partnership, responsible donor stewardship, and transparency.”
Feinberg has served in leadership roles for the vaccine and infectious disease divisions at Merck & Co., Inc., for the last 11 years. Most recently he was chief public health and science officer for Merck Vaccines.
“I have directly witnessed the devastating impact that AIDS has had on individuals, families, communities and countries around the world, especially for the most vulnerable populations,” Feinberg said. “I am honored to have the opportunity to work with the IAVI team and their tremendous partners to fulfill IAVI’s promise to be the most effective partner, catalyst and facilitator in supporting collective efforts to accelerate the development of an effective HIV vaccine. This goal remains a critically important one, and achieving it will require all of us to apply the best science and creativity along with a high level of openness to forging new models of collaboration.”